EUVIMEDEUVIMED entdecken
Open Access

Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases

Maria C Schneeweiss, Denys Shay, Sophia Ly, Richard Wyss, Sebastian Schneeweiss, Robert J Glynn, Arash Mostaghimi

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2023.5895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Maria C Schneeweiss und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Dermatitis, Atopic, Psoriasis, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Laboratory testing for the presence of tuberculosis, hepatitis, and other conditions before starting most systemic immunomodulatory agents is recommended in patients with chronic inflammatory skin diseases (CISD) but current testing patterns in the US are unclear.

Objective

To determine the prevalence of pretreatment testing that is recommended for patients with CISD (psoriasis, hidradenitis suppurativa, or atopic dermatitis). Design, Setting, and Participants This descriptive analysis of US commercial insurance claims databases from December 31, 2002, to December 31, 2020, included adult patients with CISD (psoriasis, hidradenitis suppurativa, or atopic dermatitis) who started an immunomodulatory agent, including methotrexate, tumor necrosis factor α inhibitors, interleukin (IL)–17Ai, ustekinumab, IL-23i, dupilumab, or apremilast. Main Outcomes and Measures The proportion of patients who underwent the screening tests as suggested by professional societies—including for tuberculosis, hepatitis, and liver function; complete blood cell counts; and lipid panels—were determined within 6 months before and during 2 years after treatment start.

Results

A total of 122 308 patients with CISDs (median [IQR] age, 49 [38-58] years; 63 663 [52.1%] male) starting systemic immunomodulatory treatment in the US were included. Treatment for patients with CISDs comprised methotrexate (28 684), tumor necrosis factor α inhibitors (40 965), ustekinumab (12 841), IL-23i (6116), IL-17Ai (9799), dupilumab (7787), or apremilast (16 116). Complete blood cell count was the most common test, performed in 41% (3161/7787) to 69% (19 659/28 684) of individuals before initiation across treatments. Between 11% (889/7787) and 59% (3613/6116) of patients had tuberculosis screening within 6 months before treatment, and 3% (149/4577) to 26% (1559/6097) had updated tests 1 year later. Between 13% (1006/7787) and 41% (16 728/40 965) had hepatitis panels before treatment. Low pretreatment testing levels before apremilast (15% [2331/16 116] to 45% [7253/16 116]) persisted a year into treatment (9% [816/8496] to 36% [2999/8496]) and were similar to dupilumab (11% [850/7787] to 41% [3161/7787] vs 3% [149/4577] to 25% [1160/4577]). Conclusions and Relevance In this descriptive analysis of patients with CISDs starting systemic immunomodulatory treatment in the US, less than 60% received the recommended pretreatment testing. Additional research is required to understand whether variations in testing affect patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaDermatitis, AtopicPsoriasisTuberculosisHepatitisAdultHumansMaleMiddle AgedFemaleUstekinumabMethotrexateTumor Necrosis Factor-alphaImmunomodulating AgentsPrevalenceImmunologic FactorsThalidomide

Substanzen

UstekinumabMethotrexateapremilastTumor Necrosis Factor-alphaImmunomodulating AgentsImmunologic FactorsThalidomide

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Schneeweiss, M. C., Shay, D., Ly, S., Wyss, R., Schneeweiss, S., Glynn, R. J., & Mostaghimi, A. (2024). Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.5895

Vancouver

Schneeweiss MC, Shay D, Ly S, Wyss R, Schneeweiss S, Glynn RJ, et al. Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2023.5895

BibTeX
@article{Schneeweiss2024,
  author = {Schneeweiss, Maria C and Shay, Denys and Ly, Sophia and Wyss, Richard and Schneeweiss, Sebastian and Glynn, Robert J and Mostaghimi, Arash},
  title = {Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2023.5895}
}
Kostenlos starten →